Annovis Bio Files Q1 2025 10-Q
Ticker: ANVS · Form: 10-Q · Filed: May 13, 2025 · CIK: 1477845
| Field | Detail |
|---|---|
| Company | Annovis Bio, Inc. (ANVS) |
| Form Type | 10-Q |
| Filed Date | May 13, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-Q, pharmaceuticals, financials
Related Tickers: ANVS
TL;DR
Annovis Bio (ANVS) filed its Q1 2025 10-Q. Check financials.
AI Summary
Annovis Bio, Inc. filed its 10-Q for the period ending March 31, 2025. The company, formerly known as QR Pharma, Inc., is in the pharmaceutical preparations industry. Their business address is in Malvern, PA. The filing details financial information and business operations for the first quarter of 2025.
Why It Matters
This filing provides investors with an update on Annovis Bio's financial health and operational status for the first quarter of 2025, crucial for understanding the company's trajectory.
Risk Assessment
Risk Level: medium — As a pharmaceutical company, Annovis Bio faces inherent risks related to drug development, regulatory approvals, and market competition.
Key Players & Entities
- Annovis Bio, Inc. (company) — Filer of the 10-Q
- QR Pharma, Inc. (company) — Former name of Annovis Bio, Inc.
- 20250331 (date) — End of reporting period
- Malvern, PA (location) — Business address
- 2834 (industry_code) — Standard Industrial Classification for Pharmaceutical Preparations
FAQ
What is the reporting period for this 10-Q filing?
The 10-Q filing is for the period ending March 31, 2025.
What is the company's primary industry?
The company's Standard Industrial Classification is Pharmaceutical Preparations [2834].
What was the company's former name?
The company was formerly known as QR Pharma, Inc.
Where is Annovis Bio, Inc. located?
The company's business address is 101 Lindenwood Drive, Suite 225, Malvern, PA 19355.
When was the company's name changed?
The date of the name change from QR Pharma, Inc. to Annovis Bio, Inc. was December 2, 2009.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on May 13, 2025 regarding Annovis Bio, Inc. (ANVS).